# A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

> **NCT03280563** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 144 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody
- **DRUG:** Bevacizumab
- **DRUG:** Entinostat
- **DRUG:** Exemestane
- **DRUG:** Fulvestrant
- **DRUG:** Ipatasertib
- **DRUG:** Tamoxifen
- **DRUG:** Abemaciclib

## Key facts

- **NCT ID:** NCT03280563
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-22
- **Primary completion:** 2024-09-26
- **Final completion:** 2024-09-26
- **Target enrollment:** 144 (ACTUAL)
- **Last updated:** 2025-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03280563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03280563, "A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03280563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*